This analysis examines Incyte's current position, growth strategies, and the challenges it faces in the evolving pharmaceutical landscape ... of the full-year revenue guidance for Jakafi, the ...
This analysis examines Incyte's current position, growth strategies, and the challenges it faces in the evolving pharmaceutical ... guidance for Jakafi, the company's flagship product, to between ...
FORT WORTH, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals ... Track designation to NPI-001 (N-acetylcysteine amide) tablets, Nacuity’s proprietary investigational therapy ...
New Delhi: Exemed Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct a bio-equivalence study of ...
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti tablets of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, of Otsuka Pharmaceutical Company, Ltd, it ...
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, of Otsuka Pharmaceutical Company, Ltd. (Otsuka) ...
Incyte (NASDAQ:INCY) Corporation (NASDAQ:INCY), with a market capitalization of $13.9 billion, finds itself at a critical juncture as it faces the looming expiration of patents for its flagship ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback